Propranolol diminished severity of rat EAE by enhancing immunoregulatory/protective properties of spinal cord microglia by Pilipović, Ivan et al.
Contents lists available at ScienceDirect
Neurobiology of Disease
journal homepage: www.elsevier.com/locate/ynbdi
Propranolol diminished severity of rat EAE by enhancing
immunoregulatory/protective properties of spinal cord microglia
Ivan Pilipovića, Zorica Stojić-Vukanićb, Ivana Prijića, Nebojša Jasnićc, Gordana Leposavićd,⁎
a Immunology Research Centre “Branislav Janković”, Institute of Virology, Vaccines and Sera “Torlak”, 458 Vojvode Stepe, 11221 Belgrade, Serbia
bDepartment of Microbiology and Immunology, University of Belgrade-Faculty of Pharmacy, 450 Vojvode Stepe, 11221 Belgrade, Serbia
c Institute for Physiology and Biochemistry, University of Belgrade-Faculty of Biology, Studentski trg 16, 11000 Belgrade, Serbia
dDepartment of Pathobiology, University of Belgrade-Faculty of Pharmacy, 450 Vojvode Stepe, 11221 Belgrade, Serbia








A B S T R A C T
Sympathetic dysfunction is suggested to contribute to development of multiple sclerosis and experimental au-
toimmune encephalomyelitis (EAE) alike. Considering important role of microglia in development/resolution of
neuroinflammation, contribution of noradrenaline, the key sympathetic end-point mediator, in modulation of
microglial phenotypic and functional properties in rat EAE model was examined. The study showed that nor-
adrenaline acting in neurocrine and autocrine/paracrine way might influence microglia during EAE. Propranolol
treatment over the effector phase moderated EAE course. This was associated with the increased proportion of
microglia expressing CX3CR1, the key molecule in their immunomodulatory/neuroprotective action, and up-
regulation of CX3CR1 downstream Nrf2 gene. This correlated with the increased heme oxygenase-1 (HO-1)
expression and phagocytic capacity of microglia, and their phenotypic changes mirrored in increased proportion
of CD163- and CD83-expressing cells. The enhanced HO-1 expression was linked with the decreased proportion
of microglial cells expressing IL-1β and IL-23, and possibly IL-6, followed by increased proportion of IL-
10–expressing microglia, and downregulated MCP-1/CCL2 expression. Consistently, spinal cord infiltration with
blood-borne myeloid and CD4+ T cells, as well as CD4+ T-cell reactivation/proliferation and differentiation
into highly pathogenic IL-17+ cells co-producing IFN-γ and GM-CSF were decreased in propranolol-treated rats
compared with saline-injected controls. The in vitro investigations of the effects of noradrenaline on microglia
showed that noradrenaline through β-adrenoceptor may influence Nrf2 expression also via CX3CR1-independent
route. The study suggests β-adrenoceptor–mediated neuroinflammation-promoting role of noradrenaline in EAE
via modulation of microglial Nrf2 expression, and thereby forms the basis for further translational pharmaco-
logical research to improve multiple sclerosis therapy.
1. Introduction
Multiple sclerosis (MS) is the most common autoimmune disease of
the central nervous system (CNS), which is pathohistologically char-
acterized by inflammation and neurodegeneration causing a wide
spectrum of clinical manifestations, including autonomic dysfunction
(AD) (Lassmann and van Horssen, 2011). AD observed in 45% to 84%
of MS patients leads to the fatigue, and various cardiovascular, bladder,
bowel, ocular and sexual symptoms affecting quality of life of patients
with MS (Flachenecker et al., 2003; Kodounis et al., 2005; Haensch and
Jörg, 2006). AD in MS has been related to inflammation and demyeli-
nation in specific structures within the CNS (Polak et al., 2011). Among
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these structures is locus coeruleus, a major noradrenaline source in the
brain (whose activation, particularly during stress, leads to the sym-
pathetic nervous system activation), and spinal cord (Haensch and Jörg,
2006; Polak et al., 2011). Additionally, AD is associated with altered
catecholamine release from peripheral immune cells (Rajda et al.,
2002). Specifically, higher adrenaline level in peripheral blood lym-
phocytes was found in first-attack MS patients than in healthy controls
(Rajda et al., 2002). However, during remission in relapsing–remitting
MS patients, noradrenaline levels in peripheral blood lymphocytes were
lower than in healthy subjects (Rajda et al., 2002). Also, increased
density of β-adrenoceptor on peripheral blood mononuclear cells from
MS patients was reported (Karaszewski et al., 1990; Zoukos et al.,
1992). Autonomic nervous system, particularly its sympatho-adreno-
medullary branch, is the major pathway in the cross-talk between the
CNS and the immune system (Elenkov et al., 2000; Nance and Sanders,
2007). Nevertheless, the significance of AD in the immunopathogenesis
of MS has not yet been investigated in dedicated studies. Although
target tissue critically determines autoimmune disease severity (Hill
et al., 2007), data on β2-adrenoceptor expression on CNS cells involved
in imunopathogenesis of MS are limited. There are only a few reports
pointing to astrocyte β2-adrenoceptor deficiency in MS patients as a
contributing factor to MS progression (Zeinstra et al., 2000; De Keyser
et al., 2004).
Sympathetic/adrenergic dysregulation has also been observed in the
development of experimental autoimmune encephalomyelitis (EAE)
(del Rey et al., 1982; Mackenzie et al., 1989; Pilipović et al., 2019a),
widely used group of experimental models mimicking various patho-
genic and clinical aspects of MS (Robinson et al., 2014). Moreover, the
role of β-adrenoceptor–mediated noradrenergic mechanisms in control
of the primary immune responses in Dark Agouti (DA) rat EAE model
has recently been described (Pilipović et al., 2019b). These data render
the EAE model suitable for investigating the role of adrenergic me-
chanisms in development of MS.
EAE is characterized by an ascending paralysis resulting from spinal
cord infiltration with neuroantigen-specific CD4+ T lymphocytes,
major instigators/drivers of neuroinflammation in EAE (Shin et al.,
2012), and inflammatory monocytes during the early stages of lesion
development, followed by activation of microglia and neuronal and
oligodendrocyte damage (Kim et al., 2007). Activated microglia, apart
from the synthesis of proinflammatory mediators and promoting tissue
damage upon the first wave of encephalitogenic T-cell immigration,
may assume other functions (i.e. phagocytosis, anti-inflammatory
mediator and growth factor release), to limit the CNS damage and
promote tissue recovery (Sosa et al., 2013; Thompson and Tsirka,
2017). Thus, microglia are thought to be the key player in control of the
autoimmune neuroinflammation in MS/EAE (Shin et al., 2012;
Thompson and Tsirka, 2017). Although expression of β2-adrenoceptor,
the key adrenoceptor type involved in noradrenergic immunomodula-
tion (Elenkov et al., 2000), on rodent spinal cord microglia (Tanaka
et al., 2002; Hertz et al., 2010) and alterations in EAE rat spinal cord
noradrenaline level (Leonard et al., 1990), have been revealed, there is
no data on the role of noradrenaline in modulation of spinal cord in-
flammation and damage. However, substantial evidence obtained in
unimmunized animals suggests that catecholamines may contribute to
development of microglial proinflammatory phenotype (Walker et al.,
2013; Frank et al., 2019).
Hereby reported study was undertaken to examine the putative β-
adrenoceptor–mediated role of central noradrenaline in modulating
neuroinflammation in EAE. In the first set of experiments, the influence
of immunization for EAE on spinal cord noradrenaline level and β2-
adrenoceptor expression on microglia in DA rats was examined. In the
second set of experiments, DA rats immunized for EAE (EAE rats) were
treated with propranolol, a β-adrenoceptor antagonist crossing the
blood-brain barrier (Neil-Dwyer et al., 1981), from the 8th day post
immunization (d.p.i.) over the effector phase of EAE (Prop rats). Mi-
croglial cells and CD4+ T cells recovered from Prop rats and saline-
injected controls (Sal rats) at the peak of EAE were examined for phe-
notypic and functional properties.
2. Materials and methods
2.1. Experimental animals
Three-month-old female DA rats were used in this study. The ani-
mals were bred in the animal facility of the Immunology Research
Centre “Branislav Janković” and maintained under standard laboratory
conditions (3 rats/cage, 12-h light/dark cycle, controlled temperature
and humidity), with free access to rat chow and tap water. Animal
health was monitored daily by the animal care staff and a veterinarian.
All experimental procedures and animal care were in accordance with
the Directive 2010/63/EU of the European Parliament and of the
Council on the protection of animals used for scientific purposes. The
study protocol was approved by the Ethical Committees of the
Institution and of the Republic of Serbia (Ministry of Agriculture,
Forestry and Water Economy of the Republic of Serbia - Veterinary
Directorate; permit no. 323-07-01577/2016-05/14). All experiments
complied with ARRIVE guidelines for reporting animal research.
2.2. Induction and clinical evaluation of EAE
For EAE induction, 100 μl of emulsion comprising equal volumes of
rat spinal cord homogenate in phosphate-buffered saline (PBS) and
complete Freund's adjuvant (CFA) containing 1mg/ml of heat-killed
and dried Mycobacterium tuberculosis H37Ra (Sigma-Aldrich Chemie
GmbH, Taufkirchen, Germany) was administered, followed by a sub-
cutaneous injection of 5× 108 Bordetella pertussis (Institute “Torlak”,
Belgrade, Serbia) saline suspension, as previously described in detail
(Nacka-Aleksić et al., 2015). To minimize animal suffering, the rats
were anesthetized before immunization using an intraperitoneal injec-
tion of 50mg/kg body weight (BW) of ketamine (Ketamidor, Richter
Pharma AG, Wels, Austria; 100mg/ml) and 5mg/kg BW of xylazine
(Xylased, Bioveta, Ivanovice na Hané, Czech Republic; 20mg/ml).
Starting from the 1st d.p.i., the animals were daily monitored for neu-
rological deficit by two experienced independent observers: 0, no
clinical signs; 0.5, distal tail atony; 1, complete tail atony; 2, parapar-
esis; 3, paraplegia; 4, tetraplegia or moribund state. Facilitated access to
mashed food and water was provided for all the animals which ex-
hibited clinical signs of EAE. Rats were sacrificed through transcardial
perfusion, following the deep anesthesia induced by intraperitoneal
injection of ketamine/xylazine cocktail (80mg/kg BW/8mg/kg BW).
2.3. Experimental design
Two sets of experiments were performed. In the first set of experi-
ments, spinal cords of EAE rats and non-immunized controls were ex-
amined for either (i) tissue noradrenaline level and tyrosine hydro-
xylase mRNA expression, or (ii) microglial β2-adrenoceptor expression
and microglial/CD4+ T-cell tyrosine hydroxylase expression. EAE rats
were sacrificed in the inductive phase and at the peak of the disease, on
the 8th and the 14th d.p.i., respectively. Six rats per group per experi-
ment were used. The second set of experiments was initiated by a
preliminary study examining the effects of non-selective β-AR antago-
nist propranolol treatment over the effector phase of EAE on the clinical
picture of the disease. Starting from the 8th d.p.i., rats were sub-
cutaneously administered with 10mg/kg of propranolol [(± )-pro-
pranolol hydrochloride; Sigma-Aldrich Chemie GmbH] or saline twice
daily, and monitored for clinical signs of EAE until the full recovery (9
rats per group). Aside from capacity to block all β-AR receptors without
toxic effects (Robinson et al., 2011), the dose of propranolol was se-
lected considering our previous study suggesting that it may act at the
spinal cord level to influence clinical EAE development in DA rats
(Pilipović et al., 2019b). Follow-up experiment was performed to
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elucidate cellular/molecular mechanisms of propranolol action on
clinical EAE, by assessing phenotypic/functional properties of spinal
cord microglia and infiltrating CD4+ T cells recovered at the peak of
EAE from Prop and Sal rats (6 rats per group). Additionally, in vitro
effects of noradrenaline and/or propranolol on spinal cord microglia
were examined in an experiment encompassing 6 rats sacrificed at the
peak of EAE.
2.4. Isolation of mononuclear cells
Following perfusion, spinal cords were removed and dissociated on
a 70-μm nylon cell strainer (BD Biosciences, Erembodegem, Belgium) in
ice-cold RPMI 1640 medium (Sigma-Aldrich Chemie GmbH) containing
5% fetal calf serum (FCS; Capricorn Scientific GmbH, Ebsdorfergrund,
Germany). Spinal cord single-cell suspensions were then further frac-
tioned on a discontinuous 40/70% Percoll (Sigma-Aldrich Chemie
GmbH) gradient at 1000 g for 50min. The cells collected from the in-
terface were enumerated using Neubauer chamber and 0.2% trypan
blue dye to exclude non-viable cells.
2.5. Mononuclear cell cultures
All cultures were set up using complete RPMI 1640 medium con-
taining 2mM L-glutamine (Serva, Heidelberg, Germany), 1 mM sodium
pyruvate (Serva), penicillin (100 units/ml)/streptomycin (100 μg/ml)
solution (Sigma-Aldrich Chemie GmbH), 50 μM β-mercaptoethanol and
10% FCS. For analyses of in vitro effects of noradrenaline (arterenol)
and/or propranolol, the medium was further supplemented with
100 μM of ascorbic acid. The cells were cultivated at a density of 106/
ml, in a 5% CO2 humidified atmosphere at 37 °C.
2.5.1. Restimulation for intracellular cytokine staining
For intracellular cytokine staining, freshly isolated cells were resti-
mulated for 4 h with 200 ng/ml of phorbol 12-myristate 13-acetate
(PMA, Sigma-Aldrich Chemie GmbH) and 400 ng/ml ionomycin
(Sigma-Aldrich Chemie GmbH) in the presence of 3 μg/ml of brefeldin
A (eBioscience).
For assessing neuroantigen-specific production of IL-17, to the cells
cultured overnight in the absence or in the presence of 20 μg/ml of
myelin basic protein (MBP, Sigma-Aldrich Chemie GmbH) (recall test),
brefeldin A was added for the last 4 h of culture.
2.5.2. Assessment of noradrenaline and/or propranolol effects on microglia
in culture
Cells from EAE rats were incubated in the RPMI 1640 medium alone
or pretreated with 10−6 M of arterenol [(± )-noradrenaline(+)-bitar-
trate salt, Sigma-Aldrich Chemie GmbH] for 1 h, or 10−5 M of propra-
nolol for 15min. When both antagonist and agonist were used, arter-
enol was added 15min after propranolol. The dose of arterenol was
chosen considering that (i) supraphysiological (i.e. ≥10−6 M) nora-
drenaline concentrations are required for functional changes in immune
cells in vitro (Padro and Sanders, 2014), and (ii) 10−6 M of nora-
drenaline effectively modulates rat microglial functions (Tanaka et al.,
2002). Following pretreatment, the cells were either (i) assayed for
phagocytosis, or (ii) stimulated overnight with 1 μg/ml of lipopoly-
saccharide (LPS; Sigma-Aldrich Chemie GmbH) for measurements of
supernatant cytokine concentrations by enzyme-linked immunosorbent
assay (ELISA), or cell gene expression analysis by reverse transcription-
quantitative polymerase chain reaction (RT-qPCR).
2.6. Noradrenaline measurement
For high performance liquid chromatography (HPLC) analysis,
spinal cords were snap-frozen in liquid nitrogen and immediately stored
at −70 °C. Tissue samples were homogenized in DEPROT solution
(1mg: 20 μl) containing 2% ethylene glycol tetraacetic acid, 0.1 N
HClO4 and 0.2% MgCl2, then sonicated and centrifuged (30min,
18,000 rpm, +4 °C). Collected supernatants were injected with the
autosampler of a Dionex UltiMate 3000 HPLC system (Thermo
Scientific, Sunnyvale, CA, USA) equipped with a Hibar 125–4
LiCrospher100 RP-18 (5 μm) HPLC column (Merck Millipore,
Darmstadt, Germany). Chromeleon7 Chromatography Data System
(Thermo Scientific) was used for instrument control and data acquisi-
tion. The mobile phase consisted of 98% ammonium formate buffer
(Fisher Scientific, Cambridge, UK, pH 3.6) and 2% methanol (J.T.Baker,
Griesheim, Germany) and its flow rate was set at 500 μl/min. The po-
tential for electrochemical measurements was set at +850mV and the
separation temperature at 25 °C. Noradrenaline standard solutions (DL-
noradrenaline hydrochloride) were made from the stock standard so-
lution (1mg/ml of noradrenaline in methanol) in DEPROT, with con-
centration range 0.5–25 μg/ml. If not stated otherwise, all the chemi-
cals were provided by Sigma-Aldrich Chemie GmbH.
2.7. RT-qPCR
Snap-frozen spinal cord tissue samples and mononuclear cells lysed/
homogenized in TRIzol extraction reagent (Invitrogen Life
Technologies, Carlsbad, CA, USA) were stored at −70 °C until RNA
purification. Total RNA extraction was performed using TRIzol reagent
according to the manufacturer's instructions. The RNA concentration
and purity were determined by spectrophotometric analysis (OrionTM
AquaMate 8000 from Thermo Scientific, Waltham, MA, USA). For
cDNA synthesis, a High Capacity cDNA Reverse Transcription Kit
(Applied Biosystems) was used, as suggested by the manufacturer. RT-
qPCR reaction mixtures contained 5 μl of cDNA template, 1× TaqMan
Gene Expression Master Mix with Uracil-DNA glycosylase (UDG)
(Applied Biosystems) and 1× mix of premade primer and hydrolysis
probe sets (TaqMan Gene Expression Assays, Applied Biosystems) in a
total volume of 25 μl. Reactions in triplicate were performed under the
default Applied Biosystems 7500 Real-Time PCR System conditions.
TaqMan Gene Expression Assays detailed in Supplementary Table 1
were used to analyze the expression of tyrosine hydroxylase, IL-6, heme
oxygenase-1 (HO-1), nuclear factor erythroid 2-related factor 2 (herein
referred to as Nrf2), inducible nitric oxide synthase (iNOS), arginase 1
(Arg-1), monocyte chemoattractant protein-1/C-C motif chemokine li-
gand 2 (MCP-1/CCL2) and β-actin. Target mRNA expression was as-
sessed using the SDS v1.4.0. software (Applied Biosystems) and com-
parative threshold cycle (dCt) method, with β-actin as a reference gene.
The difference between threshold cycle values of the target and re-
ference gene (dCT=Ct target – Ct reference) in each sample was cal-
culated and the target gene expression relative to the reference gene
was expressed as 2–dCt value. The ratio of iNOS to Arg-1 expression was
calculated as follows: 2–dCt iNOS/2–dCt Arg-1 (Brown et al., 2009).
2.8. Flow cytometry analysis
2.8.1. Antibodies and immunoconjugates
For immunolabeling, the following antibodies (Abs) and second step
reagents (detailed in Supplementary Table 2) were used according to
maufacturers' instructions. Unconjugated anti-tyrosine hydroxylase
from EMD Millipore (Billerica, MA, USA). Unconjugated anti-β2-adre-
noceptor (H-73), unconjugated anti-CD83 (N-15) and phycoerythrin
(PE)-conjugated donkey anti-goat IgG from Santa Cruz Biotechnology
(Dallas, TX, USA). Fluorescein isothiocyanate (FITC)-conjugated anti-
CD11b and PE-conjugated anti-CD45 from Serotec (Oxford, UK). Biotin-
conjugated anti-CD45, biotin-conjugated anti CD11b, PE-conjugated
anti-ED2 (CD163), PE-conjugated anti-IL-10, FITC/PE-conjugated anti-
CD4, peridinin-chlorophyll-protein (PerCP)-conjugated anti-TCRαβ,
PE-conjugated anti-IL17A, FITC-conjugated anti-IFN-γ, FITC-con-
jugated goat anti-rabbit IgG, PE-conjugated F(ab’)2 donkey anti-rabbit
IgG and PE-conjugated anti-Ki-67 from BD Biosciences Pharmingen
(Mountain View, CA, USA). Unconjugated anti-CX3CR1 from Abcam
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(Cambridge, UK) and unconjugated anti-IL-23 from Bioss (Woburn, MA,
USA). Alexa Fluor 647 (AF647)-conjugated anti-TCRαβ and PerCP-
conjugated streptavidin from BioLegend (San Diego, CA, USA). FITC-
conjugated anti-Foxp3, allophycocyanin-conjugated anti-CD4 and
PerCP-eFluor 710-conjugated anti-CD25 from eBioscience (San Diego,
CA, USA). AF647-conjugated anti-GM-CSF and unconjugated anti-IL-1β
from Novus Biologicals (Littleton, CO, USA).
2.8.2. Surface and intracellular antigen immunolabeling
Aliquots of freshly isolated cells (for surface antigen im-
munostaining) or cells fixed/permeabilized for intracellular antigen
immunostaining according to eBioscience protocol (http://www.
ebioscience.com/resources/best-protocols/flow-cytometry-protocols.
htm) were incubated with saturating concentrations of fluorochrome-
labeled Abs or biotin-conjugated/unconjugated Abs (30min, 4 °C, if not
stated otherwise). When biotin-conjugated/unconjugated Abs were
used, the cells were washed following the incubation and the appro-
priate second step reagents were applied. Immunolabeling of in-
tracellular cytokines was carried out at room temperature (RT).
To determine cell apoptosis, after labeling of the surface markers,
spinal cord cells were washed with PBS and then with 1× Annexin V
binding buffer (BD Bisciences Pharmingen). The cells were then in-
cubated with Annexin V-FITC (BD Biosciences Pharmingen) for 15min
at RT and collected for flow cytometry analysis.
2.8.3. Phagocytosis of latex beads
Yellow-green fluorescent carboxylated polystyrene latex beads used
for phagocytosis assay (1 μm diameter, Sigma-Aldrich Chemie GmbH)
were sonicated in an ultrasound bath for 2min at RT. Spinal cord cells
were incubated with latex beads (bead:cell ratio of 50:1) for 1 h at 37 °C
in complete RPMI 1640 medium with 5% FCS. To arrest the phagocy-
tosis, the cells were incubated on ice for 5–10min and after washing in
ice-cold PBS, subjected to surface antigen immunostaining. Cells in-
cubated at 4 °C were used to determine the positive/negative cut-off for
latex-containing (Latex+) cells in flow cytometry analysis.
2.8.4. Endocytosis of FITC-dextran
Spinal cord cells were incubated in complete RPMI 1640 medium
with 5% FCS containing 1mg/ml FITC-conjugated dextran (Sigma-
Aldrich Chemie GmbH) for 90min at 37 °C. Excess dextran was re-
moved by washing the cells in ice-cold PBS supplemented with 2% FCS
and 0.1% NaN3 and the cells were stained for surface antigens. Cells
incubated at 4 °C were used to determine the positive/negative cut-off
for dextran-containing (Dextran+) cells in flow cytometry analysis.
2.8.5. Data acquisition and analysis
For analyses, 50,000 events per sample were acquired on FACSVerse
or FACSCalibur flow cytometer (Becton Dickinson, Mountain View, CA,
USA). FlowJo software version 7.8. (TreeStar Inc., Ashland, OR, USA)
was used to determine the frequency of marker positive cells and/or
mean fluorescence intensity (MFI), expressed as MFI ratio (MFI of an-
tibody-labeled cells/MFI of unstained negative control cells)
(Reguzzoni et al., 2002), which is indicative of the antigen expression
level. Fluorescence minus one (FMO)/isotype controls were used to set
the gating boundaries, except for markers exhibiting clear bimodal
staining (Alvarez et al., 2010).
2.9. ELISA cytokine measurement
Commercially available ELISA kits were used to determine the
concentrations of secreted IL-1β (Thermo Fisher Scientific Inc.,
Rockford, IL, USA) and IL-10 (R&D Systems, Minneapolis, MN, USA) in
cell-free culture supernatants. Measurements were performed according
to the manufacturers' instructions, with detection sensitivity of
≤12 pg/ml for IL-1β and < 10 pg/ml for IL-10.
2.10. Statistical analysis
Statistical analyses were performed using GraphPad Prism Software
(version 5.00; GraphPad Software, San Diego, CA, USA). The effects of
in vivo propranolol treatment were assessed using unpaired Student's t-
test, unless indicated otherwise. The influence of immunization for EAE
on the examined parameters was evaluated using one-way analysis of
variance (ANOVA), while in vitro effects of arterenol/propranolol were
analyzed by repeated measures one-way ANOVA. Tukey test was used
for the post-hoc comparisons. The results were presented as
mean ± SEM. Values of p≤ .05 were considered significant.
3. Results
3.1. The first set of experiments: spinal cord noradrenaline level and β2-
adrenoceptor expression on microglia during EAE development
The first set of experiments was designed based on data showing β2-
adrenoceptor–mediated immunomodulatory properties of noradrena-
line (Elenkov et al., 2000), and significance of the target organ micro-
environment for the clinical outcome of EAE (Kawakami et al., 2004).
Noradrenaline level in spinal cord and β2-adrenoceptor expression on
microglia were examined.
3.1.1. Different changes in spinal cord noradrenaline level and tyrosine
hydroxylase expression in microglia during EAE development
The level of noradrenaline in spinal cord changed with EAE devel-
opment. On the 8th d.p.i., noradrenaline level in spinal cord of EAE rats
was comparable to that in control non-immunized rats (Fig. 1A).
However, on the 14th d.p.i., it was lower (p < .05) than in non-im-
munized animals (Fig. 1A). Consistently, spinal cord expression of
mRNA for tyrosine hydroxylase, the enzyme catalyzing the rate-limiting
step in catecholamine biosynthesis (Flatmark, 2000), exhibited similar
pattern of changes to that observed in noradrenaline level during EAE
development (Fig. 1A). Next, considering recent data indicating that
intrinsic myeloid cell synthesis of catecholamines serves to amplify
inflammatory cascades in these cells (Staedtke et al., 2018), tyrosine
hydroxylase expression in microglia was examined. Microglia were
identified as CD11b+CD45lo/int cells (Almolda et al., 2009) and ex-
amined using flow cytometry analysis. The gating boundary between
CD11b+CD45lo/int and CD11b+CD45hi cells was settled by analyzing
CD11b/CD45 expression on spinal cord cells recovered from non-im-
munized control rats (Fig. 1B), as previously suggested (Djikić et al.,
2014). On the 8th and 14th d.p.i., both the frequency of tyrosine hy-
droxylase+ cells and density of tyrosine hydroxylase expression in
these cells (judging by tyrosine hydroxylase MFI) were higher
(p < .01) in EAE rats compared with non-immunized controls
(Fig. 1C). Thus, it is clear that the decrease in spinal cord noradrenaline
level and tyrosine hydroxylase expression during the course of EAE
could not be ascribed to the changes in microglia.
3.1.2. Changes in β2-adrenoceptor expression on microglia during EAE
development
Next, the expression of β2-adrenoceptor on microglia was examined
to assess putative functional implications of the immunization-induced
changes in spinal cord noradrenaline level. Flow cytometry analysis
showed that CD11b+CD45lo/int microglia from both EAE rats and non-
immunized controls bear surface β2-adrenoceptor. On the 8th d.p.i.,
their frequency within spinal cord CD11b+CD45lo/int cells and the
density of β2-adrenoceptor on their surface (judging by β2-adre-
nopceptor MFI) were comparable to those in non-immunized controls
(Fig. 1D). Differently, on the 14th d.p.i., at the peak of the disease, both
the frequency of β2-adrenoceptor+ cells within spinal cord CD11b
+CD45lo/int cells and its surface density on these cells exceeded
(p < .001) the values detected in controls (Fig. 1D).
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Fig. 1. Changes in spinal cord noradrenaline concentration and microglial tyrosine hydroxylase/β2-adrenoceptor expression during EAE development.
(A) Scatter plots indicate (left) noradrenaline concentration and (right) tyrosine hydroxylase mRNA expression in spinal cord tissue samples retrieved from rats
immunized for EAE (EAE rats) on the 14th and the 8th d.p.i., or non-immunized control animals (Non-imm). Relative mRNA expression levels were determined by RT-
qPCR and shown as 2-dCt value relative to β-actin. (B) Flow cytometry density plots indicate CD45 immunostaining of CD11b+ spinal cord cells retrieved from EAE
rats at distinct stages of the disease and non-immunized control animals. The gating boundary between CD11b+CD45lo/int (R1 region) and CD11b+CD45hi cells (R2
region) was settled based on (left density plot) CD11b vs CD45 immunostaining of spinal cord cells from non-immunized healthy rats. Black flow cytometry histogram
indicates the gating strategy for CD11b+ cells, based on (shaded histogram) FMO control incubated with isotype control antibody (Ab) instead of anti-CD11b Ab. (C,
D) Black flow cytometry histograms indicate the frequencies of (C) tyrosine hydroxylase+ and (D) β2-adrenoceptor+ cells among spinal cord CD11b+CD45lo/int
microglia retrieved from EAE rats at distinct stages of the disease and non-immunized control animals. The gating boundaries for (C) tyrosine hydroxylase+ and (D)
β2-adrenoceptor+ cells were settled using (shaded histograms) FMO controls without corresponding primary Abs, incubated with secondary Abs alone. Scatter plots
indicate (left) the frequency of (C) tyrosine hydroxylase+ and (D) β2-adrenoceptor+ cells among CD11b+CD45lo/int microglia, and (right) (C) tyrosine hydroxylase
and (D) β2-adrenoceptor MFI in/on the corresponding cells from EAE rats at distinct stages of the disease and non-immunized control animals. The data are shown as
mean ± SEM (n =6 rats/group). Horizontal bars in scatter plots indicate mean values. * p≤ .05; ** p≤ .01; *** p≤ .001.
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3.2. The second set of experiments: influence of propranolol treatment
during the effector phase of EAE on clinical manifestations of the disease and
underlying immunopathogenic mechanisms
3.2.1. Propranolol administration over the effector phase of EAE decreases
the severity of the disease and reduces the number of mononuclear cells
retrieved from spinal cord at the peak of the disease
In the second set of experiments, the influence of propranolol
treatment over the effector phase of EAE on the clinical manifestations
of the disease was investigated. Prop rats, as Sal controls, developed
acute monophasic disease reaching the peak between the 13th and the
14th d.p.i. (Fig. 2A). Prop rats developed milder disease than Sal ani-
mals, judging by lower (p < .05) mean maximum neurological score
(Fig. 2A). Additionally, shorter (p < .05) duration of the clinical dis-
ease and decreased (p < .05) clinical severity index (i.e. cumulative
clinical score of each rat divided by the number of days with clinical
EAE) were found in Prop rats than in Sal ones (Fig. 2A).
In the second experiment, which was settled to examine the
influence of propranolol on immunological parameters, similar clinical
picture of EAE was observed. Spinal cord mononuclear cells recovered
at the peak of EAE were examined for the number and phenotypic and
functional properties. In accordance with milder disease, fewer
(p < .05) mononuclear cells were retrieved from spinal cord of Prop
rats compared with Sal controls (Fig. 2B).
3.2.2. Propranolol increases the frequency of CX3CR1-expressing
microglial cells and proportion of microglia with immuoregulatory/
protective properties in spinal cord at the peak of EAE
Next, the effects of propranolol on phenotypic and functional
properties of spinal cord microglia were examined. Given that signaling
mediated through C-X3-C motif chemokine receptor 1 (CX3CR1), un-
ique receptor for fractalkine (FKN, formally known as CX3CL1), ex-
pressed on microglia has the crucial role in limiting neuroinflammation
(Wolf et al., 2013), CX3CR1 surface expression on microglia was ex-
amined. Prop rats exhibited higher (p < .001) frequency of CX3CR1+
cells among microglia than Sal controls (Fig. 3A). Additionally, greater
(p < .001) density of CX3CR1 was found on microglia from Prop rats
compared with Sal rats (Fig. 3A). Given that CX3CR1-mediated sig-
naling is shown to be the key regulator of the Nrf2 transcription factor
expression (Lastres-Becker et al., 2014), Nrf2 mRNA expression level in
spinal cord cells was also investigated. Indeed, greater (p < .001)
amount of Nrf2 mRNA was found in spinal cord cells of Prop rats
compared with Sal controls (Fig. 3B).
Given that Nrf2 stimulates the expression of TAM (Tyro3, Axl, and
Mertk) receptors (Castro-Sánchez et al., 2019) essential in regulation of
phagocytosis (Ji et al., 2015), microglial cells were examined for pha-
gocytosis of fluorescent latex beads. The frequency of Latex+ cells was
higher (p < .001) among microglia from Prop rats compared with Sal
controls (Fig. 3C). Considering that noradrenaline via β-adrenoceptor
may affect phagocytosis without affecting CX3CL1/CX3CR1 axis (Rossi
et al., 1998), and that CX3CL1 expression is confined to certain neu-
rons, but not to mononuclear cells (Wolf et al., 2013), the influence of
noradrenaline (arterenol) on phagocytic capacity of microglial cells
from EAE rat spinal cord mononuclear cell cultures was also examined.
Compared with spinal cord mononuclear cell cultures grown in the
medium alone (Control), in arterenol-supplemented cultures the fre-
quency of Latex+ cells among microglia (p < .001) was decreased
(Fig. 3D). In the co-presence of propranolol, arterenol was inefficient in
this respect (Fig. 3D). Notably, the frequency of Latex+ cells among
microglia from spinal cord mononuclear cell cultures was increased
(p < .01) in the presence of propranolol alone (Fig. 3D), supporting
catecholamine production by immune cells (Laukova et al., 2013;
Staedtke et al., 2018; Pilipović et al., 2019a).
To assess if this effect of arterenol involves Nrf2, the expression of
its transcript in LPS-stimulated spinal cord mononuclear cell cultures
(LPS cultures) supplemented with arterenol and/or propranolol was
explored. In the presence of LPS, Nrf2 mRNA expression was down-
regulated (p < .05) compared with that in control cultures with
medium alone (Fig. 3E). In arterenol-supplemented LPS cultures, Nrf2
mRNA expression was decreased (p < .001) compared with those with
LPS alone (Fig. 3E). In the co-presence of propranolol, arterenol did not
significantly influence Nrf2 mRNA expression (Fig. 3E). Thus, it may be
assumed that noradrenaline influences Nrf2 expression in both
CX3CR1-dependent and CX3CR1-independent manner.
Given that the expression of CD163 on microglia is associated with
phagocytosis of cellular debris and apoptotic/necrotic cells (Zhang
et al., 2011), its expression on microglial cells was examined as well.
The frequency of CD163+ cells among CD11b+CD45lo/int microglial
cells, and the density of CD163 on their surface, were greater
(p < .001) in Prop rats than in Sal controls (Fig. 4A). Given that
CD163-expressing cells are shown to be alternatively activated cells
expressing the mannose receptor (Mammana et al., 2018), microglia
was assayed for mannose receptor-dependent endocytosis of dextran.
Indeed, the frequency of Dextran+ cells was higher (p < .001) among
Fig. 2. Propranolol treatment over the effector phase of EAE decreases the
severity of the disease and spinal cord-infiltrating cell number. (A) Line
graph indicates the mean daily clinical score of EAE in rats treated with pro-
pranolol (Prop) or administered with saline (Sal) over the effector phase of the
disease starting from the 8th d.p.i. until the full recovery, as shown in a pre-
liminary experiment. The disease duration (days), maximum neurological score
(the sum of the highest clinical scores/number of rats with clinical EAE) and
clinical severity index (the cumulative clinical score/the number of days with
clinical EAE) are given in the table. The data are shown as mean ± SEM (n =9
rats/group). * p≤ .05; ** p≤ .01; *** p≤ .001. (B) Line graph indicates the
mean daily clinical score of EAE in Prop and Sal rats, sacrificed on the 14th d.p.i.
in a follow-up experiment examining the number and phenotypic/functional
properties of spinal cord cells. Scatter plot indicates the number of spinal cord
mononuclear cells retrieved from these animals. The data are shown as
mean ± SEM (n=6 rats/group). Horizontal bars in scatter plot indicate mean
values. * p≤ .05. Except for the disease duration and spinal cord mononuclear
cell number, Mann-Whitney U test was used for statistical analysis.
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microglia from Prop rats compared with Sal controls (Fig. 4B).
Given that vesicles derived from apoptotic cells trigger strong CD83
upregulation on microglia (Fehr et al., 2013), CD83 surface expression
on microglial cells was also investigated. The frequency of CD83+
cells was higher (p < .001) within CD11b+CD45lo/int microglia from
Prop rats (Fig. 4C). Additionally, CD83 surface density was increased
(p < .01) on CD83+ cells from Prop rats compared with Sal controls
(Fig. 4C).
3.2.3. Propranolol promotes development of microglia with anti-
inflammatory properties
Considering that Nrf2 exerts anti-inflammatory effects by triggering
HO-1 expression. (Cuadrado and Rojo, 2008; Lastres-Becker et al.,
2014), its expression in spinal cord cells was also determined. In Prop
rats, the expression of HO-1 mRNA (p < .001) was enhanced (Fig. 5A).
Activation of CX3CR1/Nrf2/HO-1 pathway is associated not only
with upregulation of anti-inflammatory cytokines, but also with pre-
vention of transcriptional upregulation of proinflammatory cytokines,
and thereby with skewing of microglia towards pro-resolution M2
phenotype (Limatola and Ransohoff, 2014; Dinkova-Kostova et al.,
Fig. 3. Propranolol increases the frequencies of CX3CR1-expressing microglia and microglial cells exhibiting neuroprotective/immunoregulatory prop-
erties. (A) Right flow cytometry density plot panel indicates the frequency of CX3CR1+ cells among spinal cord CD11b+CD45lo/int microglia retrieved from rats
immunized for EAE (EAE rats) on the 14th d.p.i., after (right) propranolol (Prop) or (left) saline (Sal) administration starting from the 8th d.p.i. Gating strategy for
CD11b+CD45lo/int cells is shown in Fig. 1B. FMO control incubated with secondary antibody (Ab) alone, without anti-CX3CR1 Ab (-CX3CR1 Ab), was used to settle
the gating boundary for CX3CR1+ cells. Scatter plots indicate (left) the frequency of CX3CR1+ cells among CD11b+CD45lo/int microglia, and (right) CX3CR1 MFI
on the CX3CR1+CD11b+CD45lo/int cells from Prop and Sal EAE rats. (B) Scatter plot indicates relative expression level of nuclear factor (erythroid-derived 2)-like 2
(Nrf2) mRNA in spinal cord mononuclear cells from Prop and Sal EAE rats, determined by RT-qPCR and shown as 2-dCt values relative to β-actin. (C) Right flow
cytometry dot plot panel indicates the frequency of fluorescent latex bead-containing (Latex+) cells among spinal cord CD11b+CD45lo/int microglia retrieved from
Prop and Sal EAE rats. Scatter plot indicates the frequency of Latex+ cells among CD11b+CD45lo/int microglia from Prop and Sal EAE rats. (D) Right flow cytometry
dot plot panel indicates the frequency of Latex+ cells among CD11b+CD45lo/int microglia in cultures of spinal cord cells retrieved from EAE rats on the 14th d.p.i.
and grown in the absence (Control) or in the presence of 10−6 M of arterenol (Art) and/or 10−5 M of Prop (see Materials and methods). Scatter plot indicates the
frequency of Latex+ cells among CD11b+CD45lo/int microglia in spinal cord cell cultures supplemented with Art and/or Prop and the corresponding Control
cultures. (C, D) Left flow cytometry dot plots indicate controls incubated at 4 °C, used to settle the gating boundaries for Latex+ cells. (E) Scatter plot indicates Nrf2
mRNA expression in spinal cord mononuclear cells retrieved from EAE rats on the 14th d.p.i. and cultured overnight in the medium alone (Control) or stimulated with
lipopolysaccharide (LPS) in the absence or in the presence of Art and/or Prop (see Materials and methods). Relative mRNA expression levels were determined by RT-
qPCR and shown as 2-dCt values relative to β-actin. The data are shown as mean ± SEM (n=6 rats/group). Horizontal bars in scatter plots indicate mean values. *
p≤ .05; ** p≤ .01; *** p≤ .001.
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2018). Accordingly, microglia was assayed for cytokine profile. Con-
sidering the crucial role of IL-10 produced by M2 microglia in the re-
striction of inflammation, restoration of homeostasis and promotion of
tissue reparation (Lobo-Silva et al., 2016), microglia was examined for
IL-10 production. In keeping with the expression of CX3CR1, Nrf2 and
HO-1, the frequency of IL-10-producing cells was higher (p < .001)
among CD11b+CD45lo/int microglia from Prop rats compared with Sal
ones (Fig. 5B).
Microglial synthesis of IL-1β and IL-23 was also explored. The fre-
quency of cells producing IL-1β, the cytokine whose downregulation is
central for CX3CR1-mediated microglial neuroprotection (Bhaskar
et al., 2010), was lower (p < .001) among spinal cord microglia from
Prop rats compared with Sal rats (Fig. 5C). Besides, propranolol re-
duced (p < .001) the frequency of IL-23-producing cells among spinal
cord microglia (Fig. 5D).
Overall, our findings indicated that propranolol could promote
microglial immunomodulatory/neuroprotective functions, at least
partly, independently of CX3CL1 signaling. Hence, the production of IL-
10 and IL-1β in LPS-stimulated spinal cord mononuclear cells supple-
mented with propranolol/arterenol was also examined. Compared with
control cultures, the concentration of both cytokines was increased
(p < .001) in LPS-stimulated cultures (Fig. 5E). The addition of
arterenol to these cultures decreased (p < .001) and increased
(p < .001) the concentrations of IL-10 and IL-1β, respectively
(Fig. 5E). The effects of arterenol were completely abrogated in the
presence of propranolol (Fig. 5E). Propranolol alone increased
(p < .001) the concentration of IL-10, but decreased (p < .001) that
of IL-1β (Fig. 5E), thereby further supporting the synthesis of nora-
drenaline in microglia.
Furthermore, immunomodulatory/neuroprotective role of CX3CR1-
expressing microglia may also be accomplished indirectly, through
modulation of activity of astrocytes (Limatola and Ransohoff, 2014). As
astrocytes are the major source of IL-6 in the CNS during inflammation
(Gruol and Nelson, 1997), IL-6 mRNA in spinal cord tissue was also
explored. Propranolol administration decreased (p < .01) the expres-
sion of IL-6 transcript in spinal cord tissue (Fig. 5F).
Finally, spinal cord mononuclear cells were investigated for the
expression of mRNA for iNOS, a bona fide marker of the classically
activated proinflammatory M1 microglia (Mammana et al., 2018) and
mRNA for Arg-1, a typical marker of anti-inflammatory M2 microglia
(Shin et al., 2012; Thompson and Tsirka, 2017). Additionally, iNOS
mRNA/Arg-1 mRNA expression ratio, as an indicator of regeneration in
spinal cord injury (Kigerl et al., 2009), was calculated. The expression
of iNOS mRNA was downregulated (p < .01) (Fig. 6A), whereas that of
Fig. 4. Propranolol increases CD163 and CD83 expression on microglia and mannose receptor-dependent endocytosis. (A) Right flow cytometry density plot
panel indicates the frequency of CD163+ cells among spinal cord CD11b+CD45lo/int microglia retrieved from rats immunized for EAE (EAE rats) on the 14th d.p.i.,
after (right) propranolol (Prop) or (left) saline (Sal) administration starting from the 8th d.p.i. Gating strategy for CD11b+CD45lo/int cells is shown in Fig. 1B. Scatter
plots indicate (left) the frequency of CD163+ cells among CD11b+CD45lo/int microglia, and (right) CD163 MFI on the CD163+CD11b+CD45lo/int cells from Prop
and Sal EAE rats. (B) Right flow cytometry dot plot panel indicates the frequency of dextran-containing (Dextran+) cells among spinal cord CD11b+CD45lo/int
microglia retrieved from (right) Prop and (left) Sal EAE rats. Left flow cytometry dot plot indicates control incubated at 4 °C, used to settle the gating boundaries for
Dextran+ cells. Scatter plot indicates the frequency of Dextran+ cells among CD11b+CD45lo/int microglia from Prop and Sal EAE rats. (C) Right flow cytometry
density plot panel indicates the frequency of CD83+ cells among spinal cord CD11b+CD45lo/int microglia retrieved from (right) Prop and (left) Sal EAE rats. Scatter
plots indicate (left) the frequency of CD83+ cells among CD11b+CD45lo/int microglia, and (right) CD83 MFI on CD83+CD11b+CD45lo/int cells from Prop and Sal
EAE rats. (A, C) FMO controls incubated with (A) isotype control antibody (Ab) instead of anti-CD163 Ab (-CD163 Ab), or (C) secondary Ab alone, without anti-CD83
Ab (-CD83 Ab), were used to settle the gating boundaries for CD163+ and CD83+ cells, respectively. The data are shown as mean ± SEM (n=6 rats/group).
Horizontal bars in scatter plots indicate mean values. ** p≤ .01; *** p≤ .001.
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Arg-1 mRNA was upregulated (p < .05) in spinal cord mononuclear
cells from Prop rats compared with Sal controls (Fig. 6B). Hence, iNOS
mRNA/Arg-1 mRNA expression ratio was shifted (p < .001) towards
Arg-1 in spinal cord mononuclear cells of Prop rats (Fig. 6C).
3.2.4. Propranolol decreases the expression of MCP-1/CCL2 in spinal cord
mononuclear cells
Activation of Nrf2 is shown to prevent transcriptional upregulation
of chemokines, including MCP-1/CCL2 (Dinkova-Kostova et al., 2018).
As MCP-1/CCL2 expressed by microglia (Semple et al., 2010) is in-
volved in the spinal cord infiltration with blood-derived inflammatory
monocytes and Th17 cells (Jiang et al., 2016), its expression in spinal
cord mononuclear cells was also explored. Propranolol administration
downregulated (p < .01) the expression of MCP-1/CCL2 mRNA
(Fig. 7A). Consistently, the frequency of blood-borne myeloid cells
identified as CD11b+CD45hi cells (Almolda et al., 2009), was lower
Fig. 5. Propranolol promotes anti-inflammatory functions of microglia. (A) Scatter plot indicates heme oxygenase-1 (HO-1) mRNA expression in spinal cord
mononuclear cells retrieved from rats immunized for EAE (EAE rats) on the 14th d.p.i., after propranolol (Prop) or saline (Sal) administration starting from the 8th
d.p.i. Relative mRNA expression levels were determined by RT-qPCR and shown as 2-dCt values relative to β-actin. (B, C, D) Right flow cytometry density plot panels
indicate the frequencies of (B) IL-10+, (C) IL-1β+ and (D) IL-23+ cells among spinal cord CD11b+CD45lo/int microglia retrieved from (right) Prop and (left) Sal
EAE rats. Gating strategy for CD11b+CD45lo/int cells is shown in Fig. 1B. FMO controls, incubated with (B) isotype control antibody (Ab) instead of IL-10 Ab (-IL-10
Ab), or (C, D) secondary Ab alone, without IL-1β (-IL-1β Ab) or IL-23 (-IL-23 Ab) Abs, were used to settle the gating boundaries for IL-10+, IL-1β+and IL-23+ cells,
respectively. Scatter plots indicate the frequencies of (B) IL-10+, (C) IL-1β+and (D) IL-23+ cells among CD11b+CD45lo/int microglia from Prop and Sal EAE rats.
(E) Scatter plots indicate the concentrations of (left) IL-10 and (right) IL-1β, as determined by ELISA, in supernatants from cultures of spinal cord cells retrieved from
EAE rats on the 14th d.p.i. and grown overnight in the medium alone (Control) or stimulated with LPS in the absence or in the presence of 10−6 M of arterenol (Art)
and/or 10−5 M of Prop (see Materials and methods). (F) Scatter plot indicates relative IL-6 mRNA expression level in spinal cord tissue of Prop and Sal EAE rats,
determined by RT-qPCR and shown as 2-dCt value relative to β-actin. The data are shown as mean± SEM (n = 6 rats/group). Horizontal bars in scatter plots indicate
mean values. ** p≤ .01; *** p≤ .001.
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(p < .001) among CD11b+ cells from Prop rats compared with Sal
controls (Fig. 7B).
3.2.5. Propranolol decreases reactivation/proliferation of spinal cord-
infiltrating CD4+ T cells and their differentiation into highly pathogenic
Th17 cells at the peak of EAE
We found lower (p < .01) frequency of CD4+ T cells among
mononuclear cells retrieved from spinal cord of Prop rats compared
with Sal controls (Fig. 8A). Additionally, fewer (p < .001) spinal cord
CD4+ T cells were isolated from Prop than Sal rats (Fig. 8A). Next,
CD4+ T cells infiltrating EAE rat spinal cord were analyzed for the
expression of activation/proliferation markers and the proin-
flammatory cytokines. The frequency of cells expressing CD25 activa-
tion marker was lower (p < .05) among CD4+Foxp3- lymphocytes
retrieved from Prop rats compared with Sal ones (Fig. 8B), suggesting
their impaired activation. Additionally, the frequency of cells expres-
sing Ki-67 activation/proliferation marker among CD4+Foxp3-
lymphocytes from Prop rat spinal cord was also reduced (p < .001)
compared with Sal controls (Fig. 8C).
On the other hand, the frequency of Annexin V+ apoptotic cells
among spinal cord-infiltrating CD4+ T lymphocytes was comparable
between Prop rats and Sal controls (Fig. 8D).
Considering altered expression of the key cytokines driving/main-
taining Th17 cell differentiation (IL-1β, IL-6, IL-23) (Stritesky et al.,
2008; Ghoreschi et al., 2010) in Prop rats, the frequency and number of
spinal cord Th17 cells were also determined. Their frequency and
number were lower (p < .01) in spinal cord of Prop rats when com-
pared with Sal ones (Fig. 9A). The synthesis of IL-17 on a per cell basis
was also reduced (p < .001) in Th17 cells of Prop compared with Sal
rats, judging by the IL-17 MFI (Fig. 9A). The antigen specificity of spinal
cord Th17 cells was addressed in MBP recall test. In the absence of MBP
(Control cultures), the frequency of IL-17–producing cells among
CD4+ T cells was lower (p < .001) in spinal cord mononuclear cell
cultures from Prop than in those from Sal rats (Fig. 9B). In MBP-chal-
lenged (MBP) spinal cord mononuclear cell cultures from both groups
of rats, it was increased (p < .01) when compared with the corre-
sponding Control cultures (Fig. 9B). However, the magnitude of this
increase was lower (p < .001) in spinal cord cell cultures from Prop
compared with Sal rats (Fig. 9B). Consequently, the frequency of Th17
cells within CD4+ T cells remained lower (p < .001) in MBP cultures
from Prop rats when compared with those from Sal rats (Fig. 9B).
Considering the plasticity of Th17 cells (Cosmi et al., 2014;
Kurschus, 2015), these cells were further examined for the frequency of
highly pathogenic IFN-γ- and GM-CSF-producing cells (Kurschus,
2015). Propranolol reduced the frequency (p < .05) and the number
(p < .01) of highly pathogenic IFN-γ+GM-CSF+ Th17 cells (Fig. 9C).
4. Discussion
The study showed changes in the spinal cord noradrenaline level
and the expression of β2-adrenoceptor on microglia during EAE course,
and pointed out the mechanisms underlying noradrenaline contribution
to the disease development.
4.1. Influence of immunization for EAE on the spinal cord noradrenaline
level and expression of β2-adrenoceptor on microglia
This study confirmed the previous findings indicating that nora-
drenaline concentration in spinal cord declines during EAE course
(White et al., 1983; Krenger et al., 1986; Polak et al., 2011). AD in MS is
connected with advanced stages of disease (Vlcek et al., 2018). It is
suggested to contribute to disease progression and occurrence of re-
lapses (Racosta and Kimpinski, 2016). The reduction in spinal cord
noradrenaline level in EAE was ascribed to local, spinal cord, nora-
drenergic fiber damage (White et al., 1983). Additionally, as nora-
drenergic fibers terminating in rat spinal cord originate in locus coer-
uleus (Westlund et al., 1983), this reduction may reflect locus coeruleus
Fig. 6. Propranolol decreases iNOS/Arg-1 mRNA
expression ratio in spinal cord mononuclear
cells. (A, B) Scatter plots indicate (A) inducible ni-
tric oxide synthase (iNOS) and (B) arginase (Arg-1)
mRNA expression in spinal cord mononuclear cells
retrieved from rats immunized for EAE (EAE rats) on
the 14th d.p.i., after propranolol (Prop) or saline (Sal)
administration starting from the 8th d.p.i. Relative
mRNA expression levels were determined by RT-
qPCR and shown as 2-dCt values relative to β-actin.
(C) Scatter plot indicates iNOS/Arg-1 mRNA ex-
pression ratio in spinal cord mononuclear cells of
Prop and Sal EAE rats. The data are shown as
mean ± SEM (n=6 rats/group). Horizontal bars in
scatter plots indicate mean values. * p≤ .05; **
p≤ .01; *** p≤ .001.
Fig. 7. Propranolol decreases the MCP-1/CCL2 mRNA expression in spinal
cord mononuclear cells. (A) Scatter plot indicates MCP-1/CCL2 mRNA ex-
pression in spinal cord mononuclear cells retrieved from rats immunized for
EAE (EAE rats) on the 14th d.p.i., after propranolol (Prop) or saline (Sal) ad-
ministration starting from the 8th d.p.i. Relative mRNA expression levels were
determined by RT-qPCR and shown as 2-dCt value relative to β-actin. (B) Scatter
plot indicates the frequency of CD11b+CD45hi cells among CD11b+ spinal
cord cells of Prop and Sal EAE rats. Gating strategy for CD11b+CD45hi cells is
shown in Fig. 1B. The data are shown as mean ± SEM (n=6 rats/group).
Horizontal bars in scatter plots indicate mean values. ** p≤ .01; *** p≤ .001.
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damage (Polak et al., 2011). Indeed, the central (locus coeruleus)
noradrenaline depletion modulates clinical course of chronic relapsing
rat EAE, so that each new attack is milder than the preceding ones
(Krenger et al., 1986). Adding to the complexity, our findings showed
the increase in expression of tyrosine hydroxylase in microglia with
EAE development. This is consistent with data indicating that stimu-
lation of myeloid cells with LPS or bacteria activates intrinsic synthesis
of catecholamines to provide a self-amplifying feed-forward loop
(Staedtke et al., 2018). This loop contributes to dysregulation of
proinflammatory cytokine secretion leading to augmentation of
Fig. 8. Propranolol decreases the number of spinal cord-infiltrating CD4+ T cells, and the frequency of activated/proliferating cells among them. (A) Flow
cytometry dot plot panel indicates the frequency of CD4+ TCRαβ+ (T) cells in spinal cords retrieved from rats immunized for EAE (EAE rats) on the 14th d.p.i., after
(right) propranolol (Prop) or (left) saline (Sal) administration starting from the 8th d.p.i. Scatter plots indicate (left) the frequency and (right) the number of CD4+ T
cells in spinal cords of Prop and Sal EAE rats. (B, C) Right flow cytometry dot plot panels indicate the frequencies of (B) CD25+ and (C) Ki-67+ cells among spinal
cord CD4+Foxp3- cells retrieved from (right) Prop and (left) Sal EAE rats. FMO controls incubated with isotype control antibodies (Abs) instead of (B) anti-CD25
(-CD25 Ab) or (C) anti-Ki-67 (-Ki-67 Ab) Abs were used to settle the gating boundaries for CD25+ and Ki-67+ cells among CD4+Foxp3- lymphocytes, gated as
shown in (B, utmost left). Scatter plots indicate the frequencies of (B) CD25+ and (C) Ki-67+ cells among CD4+Foxp3- lymphocytes from Prop and Sal EAE rats. (D)
Right flow cytometry dot plot panel indicates the frequency of Annexin V+ cells among spinal cord CD4+ T cells retrieved from (right) Prop and (left) Sal EAE rats.
CD4+ T cells were gated as shown in (A). FMO control without Annexin V (‐Annexin V) was used to settle the gating boundary for Annexin V+ cells. Scatter plot
indicates the frequency of Annexin V+ cells among CD4+ T cells of Prop and Sal EAE rats. The data are shown as mean ± SEM (n=6 rats/group). Horizontal bars
in scatter plots indicate mean values. * p≤ .05; ** p≤ .01; *** p≤ .001.
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inflammation and tissue injury (Staedtke et al., 2018; Flierl et al.,
2007). It was also suggested that some other catecholamine-producing
cells participate in this feed-forward loop (Staedtke et al., 2018).
Consistently, we found augmented expression of tyrosine hydroxylase
in CD4+ T cells recovered from EAE rat spinal cord compared with
non-immunized animals (Supplementary Fig. 1). Similarly, the fre-
quency of noradrenaline-synthesizing (“noradrenergic”) cells in the
target tissues increases with the development of collagen-induced ar-
thritis (Capellino et al., 2012). This is suggested to be a mechanism
contributing to compensation for the loss of sympathetic nerve fibers
(Capellino et al., 2012). Central 6-hydroxydopamine-induced depletion
of catecholamines before the immunization for EAE prevented the
disease development (Abramsky et al., 1987; Konkol et al., 1990). Thus,
it may be assumed that they have an important role in EAE pathogen-
esis. Consistently, propranolol administration initiated before the ap-
pearance of the clinical signs of EAE diminished the severity of neu-
rological deficit and duration of the disease. However, in some other
studies propranolol treatment over the effector phase of rat EAE either
worsened the disease (Brosnan et al., 1985) or did not affect its severity
(Chelmicka-Schorr et al., 1989). These inconsistencies may be related to
Fig. 9. Propranolol decreases the number of spinal cord-infiltrating IL-17+TCRαβ+ cells, including the highly pathogenic IFN-γ/GM-CSF co-producing
ones. (A) Right flow cytometry dot plot panel indicates the frequency IL-17+TCRαβ+ (Th17) cells within spinal cord mononuclear cells retrieved from rats
immunized for EAE (EAE rats) on the 14th d.p.i., after (right) propranolol (Prop) or (left) saline (Sal) administration starting from the 8th d.p.i. FMO control incubated
with isotype control antibody (Ab) instead of anti-IL-17 Ab (-IL-17 Ab) was used to settle the gating boundary for IL-17+ cells. Scatter plots indicate (left) the
frequency and (middle) the number of Th17 cells in spinal cords, and (right) IL-17 MFI in Th17 cells of Prop and Sal EAE rats. (B) Right flow cytometry dot plot panel
indicates the frequency of IL-17+ cells among CD4+ TCRαβ+ (T) lymphocytes in cultures of spinal cord cells retrieved from (right) Prop and (left) Sal EAE rats and
grown overnight (lower) in the presence of MBP (MBP) or (upper) in its absence (Control) (see Materials and methods). FMO control incubated with isotype control
Ab instead of anti-IL-17 Ab (-IL-17 Ab) was used to (lower) settle the gating boundary for IL-17+ cells among (upper) gated CD4+ T cells. Scatter plot indicates the
frequency of IL-17+ cells among CD4+ T cells from MBP and corresponding Control spinal cord cell cultures from Prop and Sal EAE rats. Bar graph indicates the
percentage of increase in the frequency of IL-17+ cells among spinal cord CD4+ T cells from MBP cultures over the corresponding Control cultures from Prop and
Sal EAE rats. Two-way ANOVA (treatment× culturing conditions) showed significant interaction between the factors for the frequency of IL-17+ cells among CD4+
T cells (F(1,20) = 4.38; p < .05). Bonferroni post-hoc test was used. (C) Right flow cytometry dot plot panel indicates the frequency of IFN-γ+GM-CSF+ cells among
spinal cord Th17 cells retrieved from (right) Prop and (left) Sal EAE rats. Th17 cells were gated as shown in (A). FMO controls incubated with isotype control Abs
instead of (left) anti-GM-CSF (‐GM-CSF Ab) and (right) anti-IFN-γ (-IFN-γ Ab) Abs were used to settle the gating boundaries for IFN-γ+GM-CSF+ cells. Scatter plots
indicate (left) the frequency and (right) the number of IFN-γ+GM-CSF+ Th17 cells in spinal cords of Prop and Sal EAE rats. The frequency of spinal cord IFN-γ+GM-
CSF+ Th17 cells was determined using FlowJo software version 7.8. (TreeStar Inc., Ashland, OR, USA). The data are shown as mean ± SEM (n=6 rats/group).
Horizontal bars in scatter plots indicate mean values. * p≤ .05; ** p≤ .01; *** p≤ .001; ### p≤ .001. # vs Sal.
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differences in EAE models in respect of immunization protocol, rat
strain, propranolol dosage and/or duration of the drug administration
(Chelmicka-Schorr et al., 1989).
4.2. Propranolol administration over the effector phase of EAE moderates
the disease course by increasing immunomodulatory/protective capacity of
microglia
Our further research was focused on microglia. To justify this ap-
proach, in accordance with some other studies (Tanaka et al., 2002;
Hertz et al., 2010), β2-adrenoceptor was detected on the surface of
microglia. Additionally, β2-adrenoceptor expression on microglia in-
creased with EAE development. This was consistent with data in-
dicating that local decrease in noradrenaline concentration leads to
upregulation of β2-adrenoceptor expression on immune cells (Lorton
and Bellinger, 2015). Several other facts strengthened our interest in
microglia. Firstly, various stress paradigms induce microglial activation
and upregulation of expression of proinflammatory cytokines and
chemokines, and thereby exaggerate inflammatory response (Blandino
Jr. et al., 2006). Secondly, these effects of stress involve catecholamine-
dependent mechanisms (Wohleb et al., 2015). Thirdly, stress-induced
proinflammatory microglial changes are preventable by propranolol
administration (Wohleb et al., 2011). Additionally, stress is shown to
decrease the expression of CX3CR1 (Wohleb et al., 2014), the key im-
munoregulatory molecule in neuron-microglial cell cross-talk (Biber
et al., 2007). Consistently, propranolol administration to EAE rats in-
creased the proportion of CX3CR1-expressing cells in microglia.
CX3CR1 deficiency confers exacerbated EAE, as shown by severe in-
flammation and neuronal loss (Cardona et al., 2018). Thus, the increase
in the frequency of CX3CR1-expressing cells among microglia from
Prop rats was fully consistent with the greater expression of mRNA for
Nrf2 in their mononuclear spinal cord cells (Castro-Sánchez et al.,
2019). To corroborate the previous notion, rapid development and
more severe clinical presentation of EAE were associated with greater
microglial activation followed by downregulation of Nrf2 (Johnson
et al., 2010). Furthermore, augmented phagocytic capacity of microglia
from Prop rats could be related to the increased expression of Nrf2, as it
was shown to upregulate TAM receptor expression (Castro-Sánchez
et al., 2019). To additionally corroborate our findings, impaired pha-
gocytic activity of microglia was found in the absence of CX3CR1 ex-
pression in cuprizone model of demyelination (Lampron et al., 2015).
However, the analysis of the effects of arterenol on phagocytic capacity
of microglia in vitro suggested that noradrenaline, acting through β-
adrenoceptor, could diminish microglial phagocytosis in a CX3CR1-in-
dependent manner, as well. Indeed, catecholamines are shown to im-
pair splenic macrophage phagocytosis in vitro (Roy and Rai, 2004).
Additionally, as propranolol counteracted arterenol-induced down-
regulation of Nrf2 expression in LPS-stimulated spinal cord mono-
nuclear cell cultures, it may be assumed that propranolol effect on
phagocytosis was mediated by Nrf2. This assumption is consistent with
findings obtained in several other studies. Carvedilol, a third-genera-
tion β-blocker, activated Nrf2 signaling pathway in HT22 murine hip-
pocampal neuronal cell line (Ouyang et al., 2013) and PC12 rat pheo-
chromocytoma cell line (Wang et al., 2014). Additionally, in the rat
model of sepsis, propranolol induced the expression of the gene en-
coding HO-1 (Wilson et al., 2013), often used as a marker of Nrf2-de-
pendent anti-inflammatory response (Lastres-Becker et al., 2014).
In accordance with the increase in phagocytic capacity of microglia
(A-Gonzalez et al., 2017), the expression of CD163 was upregulated on
microglia from Prop rats. To add extra weight to this finding are data
indicating that the increased frequency of CD163+ microglial cells is
associated with down-modulation of neuroinflammation in acute model
of EAE, and consequent recovery from paralysis (Ahn et al., 2012). In
accordance with enhanced phagocytic capacity of microglia, the man-
nose-receptor–mediated endocytosis by microglia from Prop rats was
enhanced. Namely, phagocyting cells are shown to upregulate not only
CD163 expression, but also that of Mrc1 gene (encoding for CD206, the
mannose receptor) (A-Gonzalez et al., 2017; Mammana et al., 2018).
Moreover, the enhanced phagocytosis by microglial cells from Prop rats
correlated with upregulation in CD83 expression (Fehr et al., 2013).
The latter could be associated with acquisition of regulatory/re-
generative phenotype by microglia (Olah et al., 2012) and down-
modulation of Th cell-initiated tissue damage (Fujimoto and Tedder,
2006; Stojić-Vukanić et al., 2018).
Next, enhanced expression of the components of CX3CR1-Nrf2 axis
correlated with upregulation of HO-1-encoding gene in Prop rats
(Lastres-Becker et al., 2014; Castro-Sánchez et al., 2019). Consistently,
the proportion of microglia expressing anti-inflammatory IL-10 was
increased in Prop rats (Dinkova-Kostova et al., 2018). It is of note that
IL-10 itself is capable of inducing HO-1 production, thereby forming a
positive feedback circuit to amplify the anti-inflammatory response
(Lee and Chau, 2002). Propranolol-induced changes in CX3CR1-Nrf2
axis could also be linked with the decrease in the proportion of mi-
croglia expressing proinflammatory IL-1β and IL-23 cytokines
(Cuadrado et al., 2014; Lastres-Becker et al., 2014; Castro-Sánchez
et al., 2019). The former is particularly important as microglial cell-
derived IL-1β is a key mediator of stress response in the CNS (Blandino
Jr. et al., 2006; Wohleb et al., 2011; Frank et al., 2019). In this context,
it is noteworthy that: i) stress-induced IL-1β elevation can be prevented
by propranolol (Johnson et al., 2005), and ii) β-AR activation is shown
to augment microglial IL-1β production (Tomozawa et al., 1995; Wang
et al., 2010). Antagonizing action of propranolol on arterenol effects in
LPS cultures further supports CX3CR1-independent action of propra-
nolol on Nrf2 expression, as IL-10 and IL-1β are important targets of
Nrf2/HO-1 pathway (Ambegaokar and Kolson, 2014). Moreover, pro-
pranolol downregulated IL-6 mRNA expression in spinal cord tissue.
This could be ascribed to lower IL-6 expression not only in microglia
(Tomozawa et al., 1995; Wang et al., 2010), but also in astrocytes, due
to increased frequency of CX3CR1+ microglia (Limatola and
Ransohoff, 2014).
In accordance with the shift towards a more anti-inflammatory
microglial phenotype, iNOS/Arg-1 gene expression ratio was shifted
towards Arg-1 expression in Prop rats compared with controls. This is
consistent with upregulation of iNOS concomitant with downregulation
of Arg-1 in microglia from Nrf2-deficient mice (Rojo et al., 2010).
In accordance with the decreased expression of MCP-1/CCL2 in
spinal cord cells, fewer CD4+ T lymphocytes were recovered from
spinal cord of Prop rats (Semple et al., 2010). Additionally, the shift
towards more anti-inflammatory phenotypic and functional properties
of microglia from Prop rats correlated with fewer activated/pro-
liferating cells among CD4+ T lymphocytes compared with controls
(Schetters et al., 2018). Specifically, CX3CR1 upregulation on microglia
is associated with impaired T-cell proliferation (Krasemann et al.,
2017). Additionally, suppressive effect of propranolol on T-cell re-
activation/proliferation could also be partly associated with the in-
creased microglial IL-10 production and CD83 expression (Lobo-Silva
et al., 2016; Stojić-Vukanić et al., 2018). A less efficient activation of
CD4+ T cells is shown to render them more susceptible to apoptosis
(Rogers et al., 2001). The lack of differences in the frequency of
apoptotic cells among spinal cord CD4+ T cells from Prop and control
rats could be linked with the increased microglial phagocytic capacity,
and consequently more efficient removal of apoptotic cells in Prop rats.
In accordance with the decrease in IL-1β, IL-6 and IL-23 production/
expression, the frequency of spinal cord Th17 cells, and the most pa-
thogenic IFN-γ+GM-CSF+ Th17 ones, was reduced in Prop rats com-
pared with controls (Mufazalov et al., 2017). Thus, this could also
contribute to neurologically milder disease.
In conclusion, this study provided novel data contributing to our
understanding of the role of β-adrenoceptor–mediated action of central
noradrenaline in the development of clinical EAE. It indicates that
noradrenaline, through β-adrenoceptor, may modulate microglial
functional properties via both CX3CR1-dependent and possibly
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CX3CR1-independent mechanisms, and consequently severity of neu-
rological deficit in EAE. The putative clinical implications of these
findings are two-fold. Firstly, they suggest that microglial CX3CR1-
Nrf2/TAM(HO-1) signaling pathways should be considered as a pos-
sible therapeutic target not only in neurodegenerative diseases (Jazwa
and Cuadrado, 2010), but also in MS. In this respect, propranolol, as a
drug with safe pharmacological profile, could be a putative therapeutic
option. Secondly, the differences between herein described central and
previously reported peripheral effects of propranolol on immune cells
(Vujnović et al., 2019) suggest that caution is needed when the use of
blood-brain barrier–penetrating β-adrenoceptor targeting drugs in
therapy of MS is considered.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.nbd.2019.104665.
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